A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide (ARACOG)

Protocol No
AFT-47-ARACOG
Phase
II
Summary

We are asking you to take part in this research study because you have metastatic or
non-metastatic prostate cancer that has worsened on standard hormonal therapy. Your
doctor feels that additional therapy is indicated and has recommended that you receive
an androgen receptor (AR) directed therapy. In this study, you will be assigned to a
study treatment group to evaluate the effects of darolutamide or enzalutamide, both of
which are AR directed therapies, on cognitive testing outcomes. In order to measure
the differences in cognitive outcomes, participants will be asked to complete several
study questionnaires at designated study visits.

Description
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL